Balyasny Asset Management LLC Clovis Oncology, Inc. Call Options Transaction History

Balyasny Asset Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 16, 2021	SELL	$4.13 - $6.41 $1.65 Million - $2.56 Million	-400,000 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.82 - $7.72 $48,200 - $77,200	10,000 Added 2.56%	400,000 $2.33 Million
Q4 2018 Feb 14, 2019	SELL	$11.63 - $32.67 $58,150 - $163,350	-5,000 Reduced 1.27%	390,000 $7 Million
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $6.98 Million - $11.8 Million	237,500 Added 150.79%	395,000 $12.7 Million
Q2 2018 Aug 14, 2018	BUY	$42.06 - $62.4 $736,050 - $1.09 Million	17,500 Added 12.5%	157,500 $7.16 Million
Q1 2018 May 15, 2018	BUY	$50.12 - $67.72 $751,800 - $1.02 Million	15,000 Added 12.0%	140,000 $7.39 Million
Q4 2017 Feb 14, 2018	SELL	$57.69 - $84.58 $12.6 Million - $18.5 Million	-219,000 Reduced 63.66%	125,000 $8.5 Million
Q3 2017 Nov 14, 2017	BUY	$67.17 - $84.81 $23.1 Million - $29.2 Million	344,000	344,000 $28.3 Million

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.